Drugs Affecting Lipid Metabolism

Front Matter....Pages i-xx
Regression of Human Aortic Fatty Streaks of Early Life....Pages 1-8
Serum Cholesterol as a Risk Factor: Effects of Gender and Age....Pages 9-13
Influence of Atherogenic Lipoproteins on The Thrombotic Potential of Endothelial Cells....Pages 15-22
Plurimetabolic syndrome or syndrome X. Is it a real syndrome?....Pages 23-27
Three Liver-Enriched Transcription Factors: HNF-1, C/EBP, and Protein II are Required to Enhance Transcription of the Human Apolipoprotein B Gene....Pages 29-44
Structure-Function Relationships of Apolipoprotein B-100....Pages 45-47
Contribution of Helix-Helix Interactions to the Stability of Apolipoprotein-Lipid Complexes....Pages 49-56
Oxidatively Modified LDL and Atherosclerosis....Pages 57-68
Postprandial Hyperlipidemia and Coronary Artery Disease....Pages 69-74
Genetic Factors Affecting Lipoprotein Metabolism....Pages 75-82
Lipoprotein Assembly: A Potential Target for Drugs Affecting Lipid Metabolism....Pages 83-87
Structural Features that Determine the Functional Properties of the Loop Region of Human Lipoprotein Lipase....Pages 89-96
Molecular Genetics of Lipoprotein Lipase Deficiency....Pages 97-100
A New Case of Lipoprotein Lipase Deficiency....Pages 101-106
Modulation of Triglyceride Metabolism by Diet and Drugs....Pages 107-113
Drugs Affecting Reverse Cholesterol Transport....Pages 115-120
High Density Lipoproteins: Function in Reverse Cholesterol Transport and Maintenance of Cellular Integrity....Pages 121-129
The Expression and Regulation of Cholesterol 7α-Hydroxylase....Pages 131-138
Cholesterol Metabolism in Normo and Genetically Hyperlipidemic Rats in Aging....Pages 139-143
In Vitro Effect of Thiol- and Cysteine-Containing Compounds on the Immunological Reactivity of Human and Rhesus Monkey Lipoprotein(a)....Pages 145-150
The Interaction of Lp(A) with Liver Cells: Implications for Lipid Lowering Therapy....Pages 151-159
Metabolism of Apo(a) and ApoB-100 in Human Lipoprotein(a)....Pages 161-167
Vitamin E—Absorption, Transport in Lipoproteins, Delivery to Tissues and Antioxidant Activity....Pages 169-174
Role of the Macrophage Scavenger Receptor in the 9-Hydroxyoctadecadienoic Acid Mediated Expression of Interleukin 1β....Pages 175-181
Oxidative Damage to Circulating LDL....Pages 183-190
Dietary Advice for the Prevention of Arterial Thrombosis....Pages 191-197
Drugs Affecting High-Density Lipoprotein and Triglyceride Metabolism....Pages 199-213
Drugs Affecting Thrombosis and Atherosclerosis....Pages 215-229
Lipid Lowering: Progression and Regression of Atherosclerotic Lesions....Pages 231-239
Clinical Trials of Atherosclerosis Regression....Pages 241-249
Biochemical Mechanisms Associated with the Lipolytic Effects of Calcium Channel Blockers....Pages 251-260
Pravastatin Reduces Plasma Concentration of a More Electronegatively Charged LDL Subfraction in FH....Pages 261-268
Clinical Experience with Fluvastatin, the First Synthetic HMG-CoA Reductase Inhibitor....Pages 269-276
Secondary Prevention of Cardiovascular Disease: The Role of HMG-CoA Reductase Inhibitors....Pages 277-281
Combined Drug Treatment of Severe Hypercholesterolemia....Pages 283-292
Regression of Coronary Atherosclerosis by LDL-Apheresis....Pages 293-297
Partial Ileal Bypass — Results of the Program on the Surgical Control of the Hyperlipidemias (POSCH)....Pages 299-307
Hypercholesterolemia: Negotiating the Issues....Pages 309-315
Antiatherosclerotic Drugs: A Critical Assessment....Pages 317-331
Experimental and Clinical Evidence for a Protective Role of High-Density Lipoprotein in Coronary Heart Disease....Pages 333-338
HDL as a Risk Factor for Coronary Heart Disease: An Update on the Helsinki Heart Study....Pages 339-342
Relationship of HDL Cholesterol to Incidence of Atherosclerotic Coronary Heart Disease: The Procam Experience....Pages 343-355
The Clinical Approach to the Patients with Low HDL and Elevated Plasma Triglyceride....Pages 357-364
Familial Lipoprotein Disorders in Patients with Premature Coronary Artery Disease....Pages 365-374
Efficacy of Fenofibrate on Plasma Cholesterol in Swine with Spontaneous Hypercholesterolemia....Pages 375-382
Lipoprotein Particles Heterogeneity: Clinical and Pharmacological Implication....Pages 383-389
Fibrinogen: Pathogenetical and Therapeutical Implications in Atherosclerosis....Pages 391-398
Regression and Decrease in Progression of Coronary Artery Disease Through Lipid-Lowering Therapy....Pages 399-406
Glycation and Oxidation of Proteins: A Role in the Pathogenesis of Atherosclerosis?....Pages 407-420
A Modern View of Atherogenesis....Pages 421-425
Defective Catabolism of Oxidized LDL by J774 Murine Macrophages....Pages 427-439
Analysis of Lipid Vs. Non-lipid Effect on Atherosclerosis Development....Pages 441-446
Atherogenicity of Triglyceride-Rich Lipoproteins: Cellular Aspects....Pages 447-451
Atherogenicity of Triglyceride-Rich Lipoproteins: Clinical Aspects....Pages 453-466
Factors Influencing the Altered Lipoprotein System in Hypertriglyceridemia....Pages 467-475
Effects of Fibrates on the Altered Lipoprotein System in Hypertriglyceridemia....Pages 477-481
Triglyceride-Rich Lipoproteins: Role in Atherogenesis and Haemostasis....Pages 483-491
The Role of Plasma Membrane Cholesterol Pools in the Regulation of Cellular Cholesterol Efflux....Pages 493-498
Kinetics of Exogenous Di-Linoleyl Phosphatidylcholine and Incorporation in Plasma and RBC Lipids in Man....Pages 499-505
Alimentary Lipemia and Phospholipids....Pages 507-513
Back Matter....Pages 515-521